pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,273 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1867Endpoints1449Fierce Biotech765BioSpace757BioPharma Dive548raps249onclive165fda recalls120
therapy area
allOncology12917Rare Disease3338Immunology3024Cardiology2856Hematology2298Pulmonology2255Vaccines
  • AbbVie signs up to $2.5 B licensing deal with DISCO to develop solid tumor bispecific therapies
    AbbVie announced a licensing agreement with European biotech DISCO Pharmaceuticals that could be worth as much as $2.5 billion. The deal includes a $40 million upfront payment and future milestones…
    BioSpace · 3h agoDealPositive↗ source
  • Nine California biotech firms slash at least half of their workforces amid statewide cuts
    Workforce reductions have affected more than 1,000 biopharma employees in California so far this year, with the hardest hits falling on biotech firms. Nine companies have announced plans to cut at…
    BioSpace · 5h agoLayoffsNegative↗ source
← prev
page 1 of 131
next →
fda medwatch115
globenewswire health73
fda press62
1854
Psychiatry & CNS1230
Ophthalmology1134
Endocrinology & Metabolism807
Pain791
Nephrology785
  • Outset Medical issues safety alert for Tablo dialysis system power cords overheat risk
    The FDA’s Center for Devices and Radiological Health has posted an Early Alert after learning that certain power cords used with Outset Medical’s Tablo hemodialysis consoles and the TabloCart with…
    fda medwatch · 5h agoRegulatoryNeutral↗ source
  • MAHA PAC spent more on its own D.C. steakhouse events than on a key ally’s House race before midterm losses
    The political arm of Make America Healthy Again (MAHA) directed millions of dollars to its own operations, including a high‑profile dinner in Washington, D.C., rather than funneling that money to c…
    STAT · 1h agoNegative↗ source
  • Study finds stopping statins in older adults may lead to worse outcomes despite non-inferior label
    A new trial called STREAM examined whether older adults without prior heart attacks or strokes could safely stop taking statins. The study was presented at the American Heart Association annual mee…
    STAT · 1h agoNegative readoutNeutral↗ source
  • Three series-C funded biotechs expand hiring, including Triveni Bio’s $65 M raise
    Three biotechnology companies that announced series C financing this year are actively hiring, signaling plans to scale operations. One of the firms secured a $140 million round and maintains offic…
    BioSpace · 5h agoDealNeutral↗ source
  • GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent deal
    GSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…
    BioSpace · 21h agoApprovalPositive↗ source
  • Pfizer partners with China's Starna Therapeutics on up to $2.6B in vivo CAR-T deal for autoimmune diseases
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to develop in vivo CAR-T therapies targeting autoimmune diseases. The agreement covers three preclinical CAR-T programs, w…
    BioSpace · 20h agoDealPositive↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination, raising uncertainty for agency’s future
    The White House pulled its nomination of Heidi Overton for FDA commissioner, a move that surprised members of the Senate health committee. Overton’s removal leaves the agency without a permanent h…
    STAT · 15h agoRegulatoryNegative↗ source
  • BMS reports early Alzheimer’s psychosis data for Cobenfy showing reduced hallucinations but safety concerns remain
    At the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, Bristol Myers Squibb presented early Phase 3 ADEPT data for KarXT, marketed as Cobenfy, in patients with Alzheimer’s disea…
    BioSpace · 18h agoPositive readoutNeutral↗ source
  • Government policies strain funding and operations for small biotech firms
    Cassel Salpeter's latest healthcare investment report says that recent government actions, including FDA staff reductions, slower federal research grants and higher tariffs, are creating a tough fu…
    BioSpace · 20h agoRegulatoryNegative↗ source
  • FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failure
    The U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…
    BioSpace · 1d agoRegulatoryNegative↗ source
  • Merck halts development of BTK inhibitor nemtabrutinib after safety concerns
    Merck announced it is ending development of the oral BTK inhibitor nemtabrutinib (MK-1026), which it acquired in the $2.7 billion ArQule purchase. The decision follows a recommendation from an ext…
    BioSpace · 20h agoRegulatoryNegative↗ source
  • FDA issues complete response letter rejecting Summit Therapeutics' lung cancer drug
    The U.S. Food and Drug Administration released a complete response letter that rejects Summit Therapeutics' lung cancer candidate, providing the agency’s detailed reasons for the decision. The age…
    STAT · 20h agoCRLNegative↗ source
  • Pfizer CEO warns China will be major biotech competitor by 2030 and urges AI-driven cost cuts
    At the Jefferies Global Healthcare Conference in London, Pfizer chief Albert Bourla said China is rapidly building its biotech sector and could become the company's biggest rival by 2030, surpassin…
    BioSpace · 21h agoNeutral↗ source
  • FDA rejects Summit Therapeutics' ivonescimab, citing trial design and safety concerns
    Summit Therapeutics received a Complete Response Letter from the FDA rejecting its application for ivonescimab, a PD-1xVEGF combination intended for EGFR-mutated non-small cell lung cancer. The ag…
    BioSpace · 22h agoRegulatoryNegative↗ source
  • Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challenges
    Acquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
    BioSpace · 1d agoDealNeutral↗ source
  • Epic Systems pledges broader AI access to its EHR data and defends its competitive practices at HLTH conference
    Epic Systems executives used a panel at the HLTH conference to respond to a STAT investigation that accused the company of limiting data access for rival developers. The company said it will make…
    STAT · 11h agoRegulatoryNeutral↗ source
  • Trump administration withdraws Heidi Overton’s FDA nomination amid Senate support concerns
    The Trump administration has pulled the nomination of Heidi Overton to become the U.S. Food and Drug Administration commissioner, saying she lacked sufficient backing to win Senate confirmation. T…
    STAT · 20h agoRegulatoryNeutral↗ source
  • Debate Over Medical School Structure Emerges as U.S. Loses Measles Elimination Status
    A discussion is unfolding about whether the traditional four‑year medical school model should be broken into separate components. The idea was voiced by a medical student who asked if every part of…
    STAT · 21h agoNegative↗ source
  • Loss of Senate Appropriations Chair Susan Collins could weaken scientists’ fight against new research oversight rule
    Senator Susan Collins, the Republican chair of the Senate Appropriations Committee, was defeated in her re‑election, ending her role as the most prominent GOP ally for science advocates. Scientist…
    STAT · 1d agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination amid Senate opposition
    The White House pulled the nomination of Heidi Overton for FDA commissioner just hours before the Senate Health, Education, Labor, and Pensions (HELP) committee was set to vote. Overton, who serve…
    BioSpace · 1d agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton's nomination to lead the FDA amid Senate Republican concerns
    The White House announced it is withdrawing its nominee, Heidi Overton, for FDA commissioner. Overton, a preventive care physician who previously served in the Trump administration, faced resistan…
    STAT · 1d agoRegulatoryNegative↗ source
  • STAT+: Influential preventive services panel to meet for first time in more than a year
    A task force, meeting after a long delay, will discuss coverage of treatments for cervical cancer, perinatal depression, and alcohol use.
    STAT · 13h agoRegulatoryNeutral↗ source
  • AI scribe market sees early winners and losers as HLTH conference highlights industry shifts
    The latest AI Prognosis newsletter from STAT examines how the artificial-intelligence scribe sector is beginning to separate into clear frontrunners and laggards. At the HLTH conference, a Startup…
    STAT · 15h agoNeutral↗ source